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Introduction: Trelagliptin, a novel once-weekly oral dipeptidyl peptidase-4 (DPP-4) inhi-
bitor, has shown favorable efficacy and safety in type 2 diabetes mellitus patients. Tre-
lagliptin was launched in Japan, and is expected to be initially used for switchover from a
daily DPP-4 inhibitor in the clinical setting. Thus, the present study was carried out to
explore the efficacy and safety of trelagliptin after a daily DPP-4 inhibitor was switched to
it.
Materials and Methods: This was an open-label, phase 3 exploratory study to evalu-
ate the efficacy and safety of trelagliptin in Japanese type 2 diabetes mellitus patients
who had stable glycemic control on once-daily sitagliptin therapy. Eligible patients
received trelagliptin 100 mg orally before breakfast once a week for 12 weeks. The pri-
mary end-point was blood glucose by the meal tolerance test, and additional end-points
were glycemic control (efficacy) and safety.
Results: Altogether, 14 patients received the study drug. The blood glucose did not
markedly change from baseline at major assessment points in the meal tolerance test,
and a decrease in blood glucose was observed at several other assessment points.
Adverse events were reported in 42.9% (6/14) of patients, but all adverse events were mild
or moderate in severity, and most were not related to the study drug. No cases of death,
serious adverse events or hypoglycemia were reported.
Discussion: It is considered possible to switch a once-daily DPP-4 inhibitor to tre-
lagliptin in type 2 diabetes mellitus patients with stable glycemic control in combination
with diet and exercise therapy without any major influences on glycemic control or
safety.
INTRODUCTION
Poor medication adherence is a common issue in clinical prac-
tice, particularly with chronic asymptomatic diseases, such as
type 2 diabetes mellitus, dyslipidemia and hypertension1–4. In
patients with type 2 diabetes mellitus, it is important to
improve medication adherence to maintain favorable glycemic
control during long-term treatment3–6. Reducing the frequency
of dosing with newer drugs could provide patients with better
control by improving their adherence to medications, especially
when the medical condition tends to be chronic, as with type 2
diabetes mellitus. More than two-thirds of patients with type 2
diabetes mellitus comply poorly with prescribed oral antidia-
betic medications, and adherence is improved by decreasing the
frequency of administration7–11. One of the major causes of
low medication adherence is inconvenience associated with fre-
quent dosing. In fact, a questionnaire survey carried out inReceived 18 April 2017; revised 25 July 2017; accepted 13 August 2017
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CLINICAL TRIAL
Japan on expectations for new antidiabetic drugs in patients
with type 2 diabetes mellitus receiving an oral hypoglycemic
agent(s) showed that approximately 70% of the patients wished
for less frequent dosing12.
Trelagliptin succinate (trelagliptin) is a novel, long-acting,
highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that is
suitable take once a week13–15. A phase 2 study using once-
weekly trelagliptin at doses ranging from 12.5 to 200 mg in
patients with inadequately controlled type 2 diabetes mellitus
showed signiﬁcantly greater reductions in glycosylated hemoglo-
bin A1c (HbA1c) in the trelagliptin group compared with the
placebo group, and dose-dependency in HbA1c in the tre-
lagliptin group with favorable safety and tolerability proﬁles13.
A phase 3, randomized, double-blind, active-controlled study of
24-week treatment with oral administration of trelagliptin
100 mg once a week showed non-inferiority of trelagliptin to
the once-daily DPP-4 inhibitor, alogliptin, with favorable safety
and tolerability proﬁles comparable with those of alogliptin14. A
phase 3, open-label, long-term study of 52-week treatment with
trelagliptin 100 mg once a week as monotherapy or in combi-
nation with an existing oral antidiabetic drug showed well-toler-
ated long-term safety and efﬁcacy both with monotherapy and
combination therapies15.
In the clinical setting, it is expected that this newly developed
once-weekly DPP-4 inhibitor, trelagliptin, will initially be used
as a switchover from a daily DPP-4 inhibitor. Therefore, the
present study was carried out to explore the efﬁcacy and safety
of trelagliptin after a daily DPP-4 inhibitor was switched to it.
MATERIALS AND METHODS
Study design and patients
This was a single-center, open-label, phase 3 exploratory study
to evaluate the effect on blood glucose when the once-daily
DPP-4 inhibitor, sitagliptin 50 mg, was switched to the once-
weekly oral trelagliptin 100 mg in Japanese type 2 diabetes mel-
litus patients with stable glycemic control on sitagliptin therapy
along with diet and exercise therapy. The study comprised a
2-week screening period, a 12-week treatment period and a
1-week follow-up period (15 weeks in total).
Patients visited the study site at week -2 (start of the screen-
ing period), and were hospitalized from day -2 to day 4. After
they were discharged from the study site, patients visited the
study site on day 7, and at weeks 2, 4, 8 and 12 during the
treatment period, and week 13 (end of the follow-up period).
During the 12-week treatment period, all patients received oral
administration of trelagliptin 100 mg once a week. Patients
were required to adhere to a certain diet and exercise therapy
(if any) for the entire study period, and the investigators
instructed the patients on the prescribed calorie intake and
exercise program throughout the study period. The sample size
was a total of 14 patients who received the study drug.
Eligible patients were adults aged ≥20 years who had been
given a diagnosis of type 2 diabetes mellitus, were adhering to
a certain diet and exercise therapy, and had received sitagliptin
50 mg/day for at least 10 weeks before the start of the screen-
ing period, whose HbA1c values were stable between 6.2 and
8.4% at the start of the screening period, and ﬂuctuated within
a level of ≤5.0% from the level at the visit before the start of
the screening period and the start of the screening period.
Patients were excluded if they received any antidiabetic drugs
other than sitagliptin (50 mg/day) within 10 weeks before the
start of the screening period or during the screening period.
Patients were also excluded if they had a fasting plasma glucose
(FPG) of <70 mg/dL or ≥250 mg/dL at the start of the screen-
ing period, if they had signs of hepatic impairment (e.g. alanine
aminotransferase or aspartate aminotransferase ≥2.5-fold the
upper limit of normal, or total bilirubin of ≥34.2 mmol/L), or
if they had electrocardiogram abnormalities (e.g., QT interval
corrected for heart rate [QTcF interval] >450 ms).
The present study, including the protocol, was reviewed and
approved by the institutional review board at the clinical site,
and was carried out in accordance with the ethical principles of
the Declaration of Helsinki, the International Conference on
Harmonisation E6 (R1) Guidelines for Good Clinical Practice,
and all applicable local laws and regulations. All patients
provided written informed consent.
Assessment
The primary end-point was blood glucose measured during the
meal tolerance test, which was carried out before each meal,
2 h after starting each meal, and 4.5 h after starting dinner on
day -1, day 1, day 2 and day 3, and before breakfast and 2 h
after starting breakfast on day 7. The nutritional composition
of the test meals was approximately 25% protein, 60% carbohy-
drate and 15% fat. The composition was the same for all test
meals and for all patients. The calorie of each test meal was
determined for each patient, and kept within a range of 10%
variation from the baseline calorie intake of each patient. Dur-
ing the hospitalization period for the tests, patients were not
allowed to consume anything other than the designated meals,
except for some beverages that do not affect the evaluation of
blood glucose, and had to follow the instructions on exercise
therapy (if any).
Additional end-points were efﬁcacy variables, such as HbA1c,
FPG, glycoalbumin, DPP-4 activity, bodyweight, and insulin,
glucagon and active glucagon-like peptide-1 (GLP-1) concentra-
tions measured during the meal tolerance test. Safety end-points
included adverse events (AEs), vital signs, 12-lead electrocardio-
gram and clinical laboratory test results. Clinical laboratory tests
were carried out at an independent central laboratory (LSI
Medience Corporation, Tokyo, Japan). HbA1c was converted
from the Japan Diabetes Society values (%) to the National
Glycohemoglobin Standardization Program values (%) using
the following formula to calculate: National Glycohemoglobin
Standardization Program HbA1c (%) = 1.02 9 Japan Diabetes
Society HbA1c (%) + 0.25%. DPP-4 activity was measured by
the enzyme activity measurement method, and active GLP-1
was measured with Glucagon-Like Peptide-1 (Active) ELISA kit
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96-well plate (Merck Millipore, Darmstadt, Germany; recovery:
>60%; intra-assay variation: <15%).
Statistical analysis
Efﬁcacy evaluation was carried out on the full analysis set, com-
prising all patients who received at least one dose of the study
medication. All variables were summarized using descriptive
statistics (number of individuals; mean; standard deviation;
maximum, minimum and quartile values) and two-sided 95%
conﬁdence intervals for the mean values.
Safety evaluation was carried out on the safety analysis set,
including all patients who received at least one dose of the
study medication, and no statistical inference was made for
safety analyses. A treatment-emergent AE (TEAE) was deﬁned
as an AE of which the date of onset was on or after the start
of study medication. TEAEs were summarized and displayed
using the Medical Dictionary for Regulatory Activities-preferred
terms. Other safety data were summarized using descriptive
statistics and a shift table.
The planned number of participants was set as 14 who
received the study drug, considering the feasibility of this study.
This planned sample size was not based on statistical considera-
tion.
All statistical analyses were carried out with SAS, version 9.2
(SAS Institute, Cary, NC, USA).
The study was registered with ClinicalTrials.gov, number
NCT01751360.
RESULTS
The present study was carried out from 5 January 2013 to 8
August 2013. A total of 18 patients signed informed consent,
and of these, 14 patients received the study drug, and all of
them completed the study. The rate of compliance with
trelagliptin was 99.45% up to week 12.
The demographic and baseline characteristics of patients in
full analysis set are shown in Table 1.
For blood glucose measured during the meal tolerance test,
the mean changes from baseline and the two-sided 95% conﬁ-
dence intervals at each assessment point on days 1, 2, 3 and 7
are shown in Table 2. The mean change in the pre-breakfast
and 2-h post-breakfast blood glucose from baseline was -6.2 to
-0.4 mg/dL and -8.7 to 7.0 mg/dL, respectively, on days 1, 2,
3 and 7. The mean change in pre-lunch and 2-h post-lunch
blood glucose from baseline was -4.1 to 0.4 mg/dL and -36.4
to -10.6 mg/dL, respectively, on days 1, 2 and 3. The mean
change in pre-dinner, 2-h post-dinner, and 4.5-h post-dinner
blood glucose from baseline was -10.4 to 3.4 mg/dL, -16.4 to
12.1 mg/dL and -14.6 to 4.5 mg/dL, respectively, on days 1, 2
and 3.
The mean changes in HbA1c, FPG, glycoalbumin and body-
weight from baseline, and the two-sided 95% conﬁdence inter-
vals at the end of the treatment period are shown in Table 3.
The mean change in HbA1c, FPG, and glycoalbumin from
baseline at the end of the treatment period was 0.04%, -1.6
mg/dL and 1.01%, respectively. The mean change in body-
weight from baseline at the end of the treatment period was
0.39 kg.
The mean change in insulin, glucagon and active GLP-1 con-
centration from baseline at each assessment point (before each
meal, 2 h after starting each meal and 4.5 h after starting din-
ner) of the meal tolerance test showed that insulin, glucagon,
and active GLP-1 concentration did not markedly change at
most assessment points during the treatment period (data not
shown).
During the treatment period, 42.9% (6/14) of patients experi-
enced at least one TEAE (Table 4). All of the TEAEs were mild
(35.7% [5/14 patients]) or moderate (7.1% [1/14 patients]) in
severity. No cases of death, serious TEAEs or TEAEs leading to
discontinuation of the study drug were reported. No cases of
hypoglycemia were reported. The only acute pancreatitis-related
TEAE reported was increased lipase, which occurred in only
one out of 14 patients (7.1%) and was mild in severity. It was
considered to be related to the study drug.
DISCUSSION
Trelagliptin was approved in March 2015 and has been
launched in Japan. The evidence available to date for tre-
lagliptin suggests that it is effective with dosing once a week. In
the phase 1 study, a single dose of trelagliptin (3.125–800 mg)
had an area under the plasma concentration–time curve from
time zero to inﬁnite time and maximum concentration that
were generally dose-proportional, the median time to reach
peak concentration was 1.0–1.5 h, and the elimination half-life
in the elimination phase was 38.44–54.26 h. Findings from the
Table 1 | Demographic and baseline characteristics
Characteristic/category Overall
n = 14







Height (cm) 166.5 (8.83)
Bodyweight, day 1 (kg) 64.14 (8.11)
BMI, day 1 (kg/m2) 23.08 (1.75)
Duration of T2DM (months) 108.4 (57.44)
Creatinine clearance, day 1 (mL/min) 85.3 (15.37)
HbA1c, day 1 (%) 7.06 (0.49)
FPG, day 1 (mg/dL) 140.5 (23.25)
2-h post-breakfast blood glucose, day -1 (mg/dL) 202.1 (38.30)
Values represent the mean (standard deviation), except for age cate-
gories and sex, for which the number of patients (%) is presented. BMI,
body mass index; FPG, fasting plasma glucose; HbA1c, glycosylated
hemoglobin A1c; T2DM, type 2 diabetes mellitus.
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same study showed that inhibition of DPP-4 activity was main-
tained for 7 days. In a phase 2 study, trelagliptin showed a
dose-dependent decrease in HbA1c at doses of 12.5–200 mg
trelagliptin, which were signiﬁcant vs the placebo. At 100 mg
dosing, the mean rate of DPP-4 inhibition remained approxi-
mately 75–80% at 7 days after dosing13. In a phase 3 conﬁrma-
tory study, trelagliptin showed similar efﬁcacy and safety to
alogliptin 25 mg, and the inhibition of DPP-4 in the trelagliptin
100 mg group at 7 days after dosing showed no notable differ-
ences from that in the alogliptin group at 1 day after dosing.
In that conﬁrmatory study, the mean rate of DPP-4 inhibition
in each treatment group was maintained at 70% from week 2
to the end of the treatment period, and the incidence of TEAEs
was similar between the trelagliptin and alogliptin groups14.
Furthermore, in a phase 3 long-term study, trelagliptin showed
well-tolerated long-term safety and efﬁcacy15. These results sup-
port the potential of trelagliptin, which is suitable to be taken
once a week.
More than two-thirds of patients with diabetes have inade-
quate adherence to oral antidiabetic therapy. Several barriers
have been suggested to interfere with the treatment regimen for
type 2 diabetes mellitus, such as regimen complexity as a result
of multiple drugs or multiple daily doses, depression, and
Table 2 | Changes in blood glucose measured during the meal tolerance test
Assessment point Day -1 (observed value) Day 1 (change) Day 2 (change) Day 3 (change) Day 7 (change)
n = 14 n = 14 n = 14 n = 14 n = 14
Before breakfast
Mean (SD) 140.9 (23.70) -0.4 (6.71) -6.2 (5.42) -3.0 (7.98) -1.7 (13.21)
Two-sided 95% CI [127.18, 154.54] [-4.23, 3.52] [-9.35, -3.08] [-7.61, 1.61] [-9.34, 5.91]
2 h after starting breakfast
Mean (SD) 202.1 (38.30) -4.4 (17.88) -1.6 (30.78) 7.0 (31.93) -8.7 (25.38)
Two-sided 95% CI [179.96, 224.18] [-14.75, 5.89] [-19.41, 16.13] [-11.43, 25.43] [-23.37, 5.94]
Before lunch
Mean (SD) 139.9 (39.19) -3.7 (22.33) 0.4 (17.98) -4.1 (12.99) NA
Two-sided 95% CI [117.23, 162.49] [-16.61, 9.18] [-9.95, 10.81] [-11.57, 3.43]
2 h after starting lunch
Mean (SD) 217.4 (49.07) -10.6 (18.13) -36.4 (24.81) -28.1 (27.58) NA
Two-sided 95% CI [189.03, 245.69] [-21.11, -0.17] [-50.68, -22.03] [-44.07, -12.22]
Before dinner
Mean (SD) 141.2 (40.82) -4.6 (19.76) -10.4 (25.41) 3.4 (23.71) NA
Two-sided 95% CI [117.65, 164.78] [-15.98, 6.84] [-25.10, 4.24] [-10.33, 17.04]
2 h after starting dinner
Mean (SD) 229.1 (55.70) 12.1 (17.67) -16.4 (26.89) -13.2 (35.11) NA
Two-sided 95% CI [196.98, 261.30] [1.87, 22.27] [-31.95, -0.90] [-33.49, 7.06]
4.5 h after starting dinner
Mean (SD) 179.0 (49.48) 4.5 (28.27) -14.0 (28.12) -14.6 (29.64) NA
Two-sided 95% CI [150.43, 207.57] [-11.82, 20.82] [-30.23, 2.23] [-31.76, 2.47]
Units are in mg/dL. CI, confidence interval; NA, not applicable; SD, standard deviation.
Table 3 | Changes from baseline at the end of the treatment period in
efficacy measures
Variable Summary Statistics 95% CI
Mean SD Lower Upper
HbA1c (%) 0.04 0.36 -0.16 0.25
FPG (mg/dL) -1.6 13.93 -9.61 6.47
Glycoalbumin (%) 1.01 1.78 -0.02 2.03
Weight (kg) 0.39 1.14 -0.27 1.05
CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycosylated
hemoglobin A1c.
Table 4 | Incidence of all treatment-emergent adverse events
No. patients (%)
Overall n = 14
Patients with any TEAEs 6 (42.9)




Blood creatine phosphokinase increased 1 (7.1)
Blood urine present 1 (7.1)
Lipase increased 1 (7.1)
Protein urine present 1 (7.1)
Spinal osteoarthritis 1 (7.1)
Diabetic nephropathy 1 (7.1)
Data are expressed in number of patients (%). TEAEs, treatment-emer-
gent adverse events.
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remembering to take the doses and reﬁll them16–19. More than
half of patients taking antidiabetic drugs daily expect that the
type and number of drugs they take will be decreased. The
availability of a once-weekly oral drug will provide an addi-
tional treatment option for patients with type 2 diabetes melli-
tus and their physicians. This was the ﬁrst report of
exploratory evaluation of the efﬁcacy and safety of once-weekly
trelagliptin 100 mg after the once-daily DPP-4 inhibitor, sita-
gliptin 50 mg, was switched to it in Japanese type 2 diabetes
mellitus patients with stable glycemic control with sitagliptin in
combination with diet and exercise therapy.
In the present study, the mean change from baseline in
blood glucose concentrations was measured during the meal
tolerance test. Blood glucose did not change markedly at major
assessment points in the meal tolerance test, and a decrease in
blood glucose was observed at several other assessment points
(e.g., 2 h after starting lunch on days 1, 2 and 3). There were
no cases of hypoglycemia. There were also no major changes
in the other efﬁcacy parameters, such as HbA1c and FPG.
Regarding safety, we previously demonstrated that trelagliptin
shows a similar safety proﬁle as a once-daily DPP-4 inhibitor,
alogliptin14. The present study also showed favorable safety and
tolerability proﬁles of once-weekly oral trelagliptin after the
once-daily DPP-4 inhibitor sitagliptin was switched to it, and
did not show any new safety signals. These results show that
trelagliptin can be initiated as a switchover from a once-daily
DPP-4 inhibitor without a major inﬂuence on glycemic control
and safety.
There were some limitations on generalizing the results of
the present study. First, this study was carried out exploratively
and involved just 14 patients, a number that was not based on
statistical consideration. Second, this study was carried out as
an open-label study and a control group was not set, and natu-
ral variations in patients or inﬂuence due to participation in
this clinical trial with the hospitalization period from day -2 to
day 4 were not taken into consideration. Finally, only Japanese
patients were enrolled in this study. Therefore, a further study
will be warranted to investigate the efﬁcacy, as well as safety, in
greater numbers of patients including a control group and/or a
non-Japanese patient population.
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